Gleb Kuznetsov of Manifold Bio discusses how artificial intelligence and high-throughput in vivo platforms transform drug discovery and protein design. Kuznetsov describes Manifold Bio's platform for de novo protein design and high-throughput in vivo measurement. They explain how molecular barcoding and million-plex animal assays accelerate discovery, address tissue targeting challenges such as the blood-brain barrier and integrate AI-driven design into empirical pipelines. Kuznetsov argues that Manifold Bio inverts traditional discovery bottlenecks by optimizing directly in living systems, which materially increases preclinical success probabilities and enables solutions to previously intractable problems. Analysts and hosts note the platform's commercial flexibility balancing proprietary programs with partnerships and its ability to feed frontier models such as Claude with rich empirical data to accelerate iteration and decision making. Gemma Allen of theCUBE Research facilitates the discussion recorded at the New York Stock Exchange's NYSE Wired: AI in Bio event.